Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Istvan Redei

Hematology Chicago, IL Medical Doctor

NPI 1306818109 CMS profile 285616

2361 Paysphere Circle, Chicago, IL 60674

Open in the dashboard

General payments

$5,108

134 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$52,054 paid to institutions, not to them · program years 2020–2023

Through program year 2023, Istvan Redei of Chicago, IL is reported in the CMS Open Payments database as having received $5,108 across 134 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $52,054 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 51st percentile of Hematology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $235 8
2022 General $2,354 11
2021 General $422 11
2020 General $341 18
2019 General $1,757 86

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Istvan Redei
  • Hematology median
  • Middle half of Hematology
  • National median

In program year 2025, general payments to Istvan Redei were reported at $0. Among 733 Hematology profiles paid that year, the median was $1,155 and the middle half received between $135 and $8,023.

Show as a table
Year Istvan Redei Hematology median Middle half National median
2019 $1,757 $1,012 $122–$9,834 $163
2020 $341 $1,475 $115–$9,198 $114
2021 $422 $1,470 $125–$7,444 $132
2022 $2,354 $1,371 $139–$8,471 $149
2023 $235 $1,295 $147–$11,010 $160
2024 $0 $1,286 $146–$9,230 $164
2025 $0 $1,155 $135–$8,023 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Kite Pharma, Inc. $1,600 1 payment
  2. BeiGene USA, Inc. $679 3 payments
  3. Novartis Pharmaceuticals Corporation $372 18 payments
  4. Seattle Genetics, Inc. $320 13 payments
  5. Celgene Corporation $262 10 payments
  6. Pfizer Inc. $236 20 payments
  7. Janssen Biotech, Inc. $229 13 payments
  8. Amgen Inc. $227 9 payments
  9. AstraZeneca Pharmaceuticals LP $220 5 payments
  10. Genentech USA, Inc. $142 7 payments
  11. Other $821 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $2,789 130 payments
  2. Consulting Fee $2,125 2 payments
  3. Education $194 2 payments
Products named General payments · program years 2019–2023
  1. Tecartus $1,600 1 payment
  2. BRUKINSA $679 3 payments
  3. DARZALEX $229 13 payments
  4. CALQUENCE $220 5 payments
  5. ADCETRIS $201 11 payments
  6. XGEVA $186 7 payments
  7. TASIGNA $177 9 payments
  8. IMBRUVICA $158 9 payments
  9. Pomalyst $155 5 payments
  10. BOSULIF $148 15 payments
  11. Other $2,187 122 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

134 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record